Peptide-drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo.

Abstract excerpt

Peptide-drug conjugates (PDCs) represent a targeted cancer therapy strategy that combines tumor-homing peptides with potent cytotoxic payloads, offering a promising alternative to antibody-drug conjugates (ADCs) through improved tissue penetration, synthetic accessibility, and tumor selectivity. Auristatins (MMAE, MMAF, etc.), which are synthetic analogues of antimitotic dolastatin 10 (Dol-10), are widely used as...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Screening Assays, Antitumor
• Share to Erb-b2 Receptor Tyrosine Kinases